Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
06/2005
06/08/2005EP1537873A1 The pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof
06/08/2005EP1537228A2 Modulators of angiogenesis
06/08/2005EP1537207A2 Recombinant colstridium neurotoxin fragments
06/08/2005EP1536834A2 Design of chemokine analogs for the treatment of human diseases
06/08/2005EP1536684A2 Method for the prevention and/or treatment of atherosclerosis
06/08/2005EP1089735B1 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists
06/08/2005EP1001797B1 Soya extract, process for its preparation and pharmaceutical composition
06/08/2005EP0975318B1 Oxidizing composition and uses for dyeing, permanently setting or bleaching keratin fibres
06/08/2005CN1625565A Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions
06/08/2005CN1625549A Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
06/08/2005CN1625411A Combination of a NSAID and a PDE-4 inhibitor
06/08/2005CN1625392A Composition for inhalation
06/08/2005CN1623985A Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
06/08/2005CN1623602A Vaccines
06/08/2005CN1623543A Organic compounds
06/08/2005CN1205205C Sodium-hydrogen exchanger type 1 inhibitor crystals
06/08/2005CN1205187C New amidino derivatives and their use as thrombin inhibitors
06/08/2005CN1204885C Pharmaceutical composition contg. fenofibrate and preparation method
06/07/2005US6903186 Analogues of GLP-1
06/07/2005US6902744 Exendin agonist formulations and methods of administration thereof
06/07/2005US6902736 Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same
06/07/2005US6902728 For treating or preventing rejection of transplanted organs, tissues or cells; particularly, use of Met-RANTES together with cyclosporin A to produce pharmaceutical composition for treatment of renal allograft transplant rejection
06/07/2005CA2222482C Non-virulent mycoplasma synoviae and vaccine thereof
06/07/2005CA2186039C New oral pharmaceutical dosage form
06/07/2005CA2092863C Cosmetic composition
06/07/2005CA2068790C Antiviral compounds
06/02/2005WO2005048957A2 Novel insertion sites in pox vectors
06/02/2005WO2005048956A2 Estradiol-related compounds and methods of use as anti-tumor agents
06/02/2005WO2005048955A2 Preloading with macular pigment to improve photodynamic treament of retinal vascular disorders
06/02/2005WO2005048954A2 Continuous process for producing hydroxyazapirones by oxidation
06/02/2005WO2005048953A2 Amide derivatives as kinase modulators
06/02/2005WO2005048951A2 A novel human g-protein coupled receptor, hgprbmy8, expressed highly in brain
06/02/2005WO2005048950A2 Tumor and infectious disease therapeutic compositions
06/02/2005WO2005048948A2 Urea derivatives as kinase modulators
06/02/2005WO2005048947A2 Oral delivery system and method for making same
06/02/2005WO2005048946A2 Treatment for burn victims and animal carcasses
06/02/2005WO2005048945A2 Hydroxylamine substituted imidazo ring compounds
06/02/2005WO2005048944A2 Activatable photodynamic therapy agents
06/02/2005WO2005048943A2 Compositions and methods for synergistic induction of antitumor immunity
06/02/2005WO2005048942A2 Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
06/02/2005WO2005048941A2 Novel substituted oxy-nitriles
06/02/2005WO2005048940A2 Nutraceutical mangosteen tea
06/02/2005WO2005048938A2 Anti-pecam therapy for metastasis suppression
06/02/2005WO2005048937A2 Package for pharmaceutical formulation
06/02/2005WO2005048936A2 Modulators of dimethylarginine dimethylaminohydrolase and methods of use thereof
06/02/2005WO2005048935A2 Methods of modulating immunity
06/02/2005WO2005048934A2 Mangosteen protein supplement
06/02/2005WO2005048933A2 Oxime substituted imidazo ring compounds
06/02/2005WO2005048932A2 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
06/02/2005WO2005048931A2 Dissolving thin film xanthone supplement
06/02/2005WO2005048930A2 Surfactant-based gel as an injectable, sustained drug delivery vehicle
06/02/2005WO2005048928A2 Methods for treating viral infection
06/02/2005WO2005048926A2 Methods for treating pain
06/02/2005WO2005048925A2 Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
06/02/2005WO2005048923A2 Extended release venlafaxine formulation
06/02/2005WO2005048922A2 Sulfonylaminovalerolactams and derivatives thereof as factor xa inhibitors
06/02/2005WO2005048919A2 Preventative effects of morinda citrifolia on mammary breast cancer
06/02/2005WO2005048918A2 Anthrax vaccine
06/02/2005WO2005048916A2 Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
06/02/2005WO2005048915A2 Renoprotective and lipid lowering oral compositions
06/02/2005WO2005048914A2 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
06/02/2005WO2005048912A2 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
06/02/2005WO2005039492A9 Improved combination bacteriolytic therapy for the treatment of tumors
06/02/2005WO2005039491A9 Certain improved combination bacteriolytic therapy for the treatment of tumors
06/02/2005WO2005037197A3 Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
06/02/2005WO2005032478A3 Treatment for diabetic microvascular and macrovascular complications
06/02/2005WO2005032470A3 Compositions and methods for treating burns
06/02/2005WO2005027823A3 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
06/02/2005WO2005025497A3 Hpv cd8+ t-cell epitopes
06/02/2005WO2005018577A3 11-deoxy-6,9-ether erythromycin compounds
06/02/2005WO2005018575A3 Estrogen receptor modulators and uses thereof
06/02/2005WO2005018565A3 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
06/02/2005WO2005016245A3 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
06/02/2005WO2005016225A3 Stable pharmaceutical composition of rabeprazole
06/02/2005WO2005013889A9 Truncated fragments of alpha-synuclein in lewy body disease
06/02/2005WO2005013884A3 Methods for preventing neurological events
06/02/2005WO2005009380A3 Pharmaceutical formulations
06/02/2005WO2005009349A3 Composition and method for treating neurological disorders
06/02/2005WO2005007120A3 System and method for treating nausea and vomiting by vagus nerve stimulation
06/02/2005WO2005002509A3 Dna vectors
06/02/2005WO2005000230A3 Methods of treating hyperproliferative cell disorders
06/02/2005WO2004110384A3 Hiv-1 envelope glycoproteins having unusual disulfide structure
06/02/2005WO2004110366A3 Sunscreen composition
06/02/2005WO2004108081A3 Oligonucleotide synthesis with alternative solvents
06/02/2005WO2004105698A3 Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders
06/02/2005WO2004103307A3 Method of use of five and fifteen carbon fatty acids
06/02/2005WO2004098500A3 CARBACEPHEM ss-LACTAM ANTIBIOTICS
06/02/2005WO2004096143A3 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
06/02/2005WO2004096136A3 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
06/02/2005WO2004093797A3 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
06/02/2005WO2004093784A3 Systems and methods for blood glucose sensing
06/02/2005WO2004087058A3 Targeted mhc class i alpha3 vaccine delivery systems
06/02/2005WO2004078132A3 Automated insomnia treatment system
06/02/2005WO2004073590A3 Diagnostics and therapeutics for deseases associated with g-protein coupled receptor prostaglandin f2-alpha (prostaglandin f2-alpha)
06/02/2005WO2004071414A3 Therapeutic anti-hcv (al9) compounds
06/02/2005WO2004060310A8 Human growth hormone crystals and methods for preparing them
06/02/2005WO2004041212A3 Apkc isoforms in nervous system disorders and cancer
06/02/2005WO2004037182A3 Active specific immunotherapy of cancer metastasis
06/02/2005WO2004034975A3 Sustained release profile modification
06/02/2005US20050120398 Animal model for HCV infection
1 ... 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 ... 295